Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amprenavir
Drug ID BADD_D00136
Description Amprenavir is a protease inhibitor used to treat HIV infection.
Indications and Usage For the treatment of HIV-1 infection in combination with other antiretroviral agents.
Marketing Status Discontinued
ATC Code J05AE05
DrugBank ID DB00701
KEGG ID D00894
MeSH ID C095108
PubChem ID 65016
TTD Drug ID D0A0OO
NDC Product Code Not Available
Synonyms amprenavir | tetrahydro-3-furyl N-(3-(4-amino-N-isobutylbenzenesulfonamido)-1-benzyl-2-hydroxypropyl)carbamate | (3S-(3R*(1R*,2S*)))-(3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl) tetrahydro-3-furanyl carbamate | VX 478 | VX-478 | Vertex VX478 | Agenerase
Chemical Information
Molecular Formula C25H35N3O6S
CAS Registry Number 161814-49-9
SMILES CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Insulin resistanceLipoprotein lipaseP06858T2869210566684; 10996400; 15865214; 14523274
Insulin resistanceAdiponectinQ15848T1557210566684; 10996400; 15865214; 14523274
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Insulin resistance14.06.02.003; 05.06.02.003--Not Available
Liver function test abnormal13.03.01.013--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myositis15.05.01.001--
Nausea07.01.07.001--
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001--Not Available
Neutropenia01.02.03.004--Not Available
Opportunistic infection11.01.08.007--Not Available
Paraesthesia17.02.06.005--
Pruritus23.03.12.001--
Rash23.03.13.001--Not Available
Rhabdomyolysis15.05.05.002--
Skin disorder23.03.03.007--Not Available
Sleep disorder19.02.04.001--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Tremor17.01.06.002--
Vomiting07.01.07.003--
Fat redistribution14.08.04.002--Not Available
Lipodystrophy acquired23.07.01.003; 14.08.04.008--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.01.015--Not Available
Paraesthesia oral07.05.03.003; 17.02.06.008--Not Available
Abdominal symptom07.01.06.007--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages